2024 World Conference on Lung Cancer (WCLC) - Posters-P2.11C.01 With Eyes on the Future: Prospective Evaluation of Immune-Related Adverse Events in Patients with Lung Cancer

P2.11C.01 With Eyes on the Future: Prospective Evaluation of Immune-Related Adverse Events in Patients with Lung Cancer

Pdf Summary

This ongoing study, conducted by researchers at the Dana-Farber Cancer Institute and Harvard Medical School, aims to evaluate immune-related adverse events (irAEs) in lung cancer (LC) patients undergoing immunotherapy with immune checkpoint inhibitors (ICIs). The research provides a real-world assessment of ICI tolerability, an area previously lacking comprehensive data.<br /><br />The study involves 36 patients from Dana-Farber with lung cancer stages I to IV, receiving single-agent immunotherapy. Different ICIs used include Pembrolizumab (50%), Durvalumab (19.4%), with smaller percentages for other ICIs like Nivolumab, Atezolizumab, and Ipilimumab. Data is collected using the ePRO-CTCAE tool at multiple points during treatment and includes demographics and patient-reported symptoms.<br /><br />Key findings from this report include frequent high-severity symptoms such as shortness of breath and coughing. Other symptoms of note, albeit less common, include severe nausea and abdominal pain. Fatigue or a lack of energy was prevalent, affecting 27 out of 34 patients. Anorexia was reported by 14 patients, with 8 noting it interfered significantly with their daily activities. Other symptoms like diarrhea, dry mouth, and difficulty tasting were noted but were less frequent.<br /><br />The study is significant as it provides prospective evaluations of irAEs linked to ICIs in patients with lung cancer. Understanding the time-dependent nature of these adverse events is vital for improving patient management. Further investigation into how these symptoms evolve over time is planned to enhance patient care and management strategies as the study progresses.

Asset Subtitle

Lauren Kiel

Meta Tag

Speaker Lauren Kiel

Topic Metastatic NSCLC – Immunotherapy

Keywords

immune-related adverse events

lung cancer

immunotherapy

immune checkpoint inhibitors

Pembrolizumab

Durvalumab

patient-reported symptoms

Dana-Farber Cancer Institute

Harvard Medical School

ICI tolerability